Inactive Instrument

ArQule, Inc.

Equities

US04269E1073

Biotechnology & Medical Research

ArQule : To Report Third Quarter 2016 Financial Results On November 7, 2016

December 04, 2016 at 09:08 pm EST

BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter 2016 before the market opens on Monday, November 7, 2016. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update.

The live webcast can be accessed in the 'Investors & Media' section of our website, www.arqule.com, under 'Events & Presentations '. You may also listen to the call by dialing (877) 868-1831 within the U.S. or (914) 495-8595 outside the U.S. A replay will be available two hours after the completion of the call and can be accessed in the 'Investors & Media' section of our website, www.arqule.com, under 'Events and Presentations'.

About ArQule

ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule's lead product, in phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase, for second-line treatment of hepatocellular carcinoma in partnership with Daiichi Sankyo in the West and Kyowa Hakko Kirin in Asia. ArQule's proprietary pipeline includes: ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in phase 2 for iCCA and in phase 1b for multiple oncology indications; ARQ 092, a selective inhibitor of the AKT serine/threonine kinase, in phase 1 for multiple oncology indications as well as ultra-rare Proteus syndrome, in partnership with the National Institutes of Health (NIH); ARQ 751, a next generation AKT inhibitor, in phase 1 for patients with AKT1 and PI3K mutations; and ARQ 761, a β-lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell necrosis, in phase 1/2 in multiple oncology indications in partnership with the University of Texas Southwestern Medical Center. ArQule's current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company's proprietary library of compounds. For more information, please follow us on Twitter and LinkedIn.

View source version on businesswire.com:http://www.businesswire.com/news/home/20161024005046/en/

ArQuleDawn Schottlandt, 781-994-0300
Sr. Director, Investor Relations/Corp. Communications
www.arqule.com

Source: ArQule, Inc.

News Provided by Acquire Media

ArQule Inc. published this content on 07 November 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 05 December 2016 02:08:04 UTC.

Original documenthttp://investors.arqule.com/releasedetail.cfm?ReleaseID=994947

Public permalinkhttp://www.publicnow.com/view/5C388D81B71EA349F0A818A563FCA0D565C94A94

Latest news about ArQule, Inc.

ArQule, Inc. Announces Management Changes	20-01-16	CI
ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P TMI Index	20-01-16	CI
ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P Biotechnology Select Industry Index	20-01-16	CI
ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P Global BMI Index	20-01-16	CI
Merck Sharp & Dohme Corp. completed the acquisition of ArQule, Inc..	20-01-14	CI
Wall St. falls as Apple, health shares drag, tariff deadline looms	19-12-09	RE
Transcript : ArQule, Inc. - Special Call	19-12-09
ArQule, Inc. Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting	19-12-09	CI
Merck Sharp & Dohme Corp. entered into a definitive agreement to acquire ArQule, Inc. for $2.4 billion.	19-12-08	CI
ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting	19-11-25	CI
ArQule, Inc. Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies	19-11-06	CI
Transcript : ArQule, Inc., Q3 2019 Earnings Call, Oct 30, 2019	19-10-30
ArQule, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-10-30	CI
ArQule, Inc. Provides Financial Guidance for 2019	19-10-30	CI
ArQule, Inc. Presents Recent Data on ARQ 751	19-10-29	CI
ArQule Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformations at 2019 ASHG Annual Meeting	19-10-21	CI
ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	19-10-16	CI
ArQule, Inc. Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum	19-10-02	CI
Certain Common Stock of ArQule, Inc. are subject to a Lock-Up Agreement Ending on 23-SEP-2019.	19-09-22	CI
Certain Warrants of ArQule, Inc. are subject to a Lock-Up Agreement Ending on 23-SEP-2019.	19-09-22	CI
Certain Options of ArQule, Inc. are subject to a Lock-Up Agreement Ending on 23-SEP-2019.	19-09-22	CI
Transcript : ArQule, Inc. Presents at Citi's 14th Annual Biotech Conference, Sep-04-2019 03:00 PM	19-09-04
Transcript : ArQule, Inc., Q2 2019 Earnings Call, Aug 07, 2019	19-08-07
ArQule, Inc. Provides Financial Guidance for the Fiscal Year 2019	19-08-07	CI
Arqule, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-07	CI

Chart ArQule, Inc.

Duration

Period

More charts

Company Profile

ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company's product candidates include ARQ 531, Miransertib (ARQ 092), ARQ 751, Miransertib (ARQ 092) and ARQ 751. ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase (BTK). ARQ 092 is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. ARQ 751 is a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K). ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-1.82%	41.35B
LONZA GROUP AG	+42.55%	40.38B
MODERNA, INC.	+2.56%	39.05B
CELLTRION, INC.	-12.11%	26.67B
ICON PUBLIC LIMITED COMPANY	+3.09%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.36B
MEDPACE HOLDINGS, INC.	+22.12%	11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.74%	11.68B
UNITED THERAPEUTICS CORPORATION	+7.75%	11.15B

Other Biotechnology & Medical Research